Calquence 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0022 
Minor change in labelling or package leaflet not 
16/02/2024 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10887
Periodic Safety Update EU Single assessment - 
22/06/2023 
16/08/2023 
Refer to Scientific conclusions and grounds recommending 
/202210 
acalabrutinib 
the variation to terms of the Marketing Authorisation(s)’ for 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
PSUSA/10887/202210. 
IB/0019 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
21/06/2023 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0020 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
14/06/2023 
16/08/2023 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0018 
B.II.d.2.a - Change in test procedure for the finished 
26/05/2023 
n/a 
product - Minor changes to an approved test 
procedure 
II/0015 
Update of section 5.1 of the SmPC based on the 
12/05/2023 
16/08/2023 
SmPC 
For more information, please refer to the Summary of 
interim report of study ACE-CL-007; a randomized, 
multicenter, open-Label, 3-arm phase 3 study of 
obinutuzumab in combination with chlorambucil, 
ACP-196 in combination with obinutuzumab, and 
ACP-196 monotherapy in subjects with previously 
untreated chronic lymphocytic leukemia. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Product Characteristics. 
IAIN/0017 
A.5.a - Administrative change - Change in the name 
03/05/2023 
16/08/2023 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X/0009/G 
This was an application for a group of variations. 
15/12/2022 
20/02/2023 
SmPC, 
Annex I_2.(d) Change or addition of a new 
pharmaceutical form 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
Labelling and 
PL 
II/0013 
Update of section 5.1 of the SmPC in order to update 
12/01/2023 
16/08/2023 
SmPC 
For more information, please refer to the Summary of 
efficacy and safety information based on final results 
Product Characteristics. 
from study ACE-CL-309 (A Phase 3 randomized 
open-label active-control study investigating 
Calquence for the Treatment of Subjects With 
Relapsed or Refractory Chronic Lymphocytic 
Leukaemia) listed as a category 3 study in the RMP. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/10887
Periodic Safety Update EU Single assessment - 
01/12/2022 
n/a 
PRAC Recommendation - maintenance 
/202204 
acalabrutinib 
PSUSA/10887
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
/202110 
acalabrutinib 
II/0011 
Submission of an updated RMP version 3 in order to 
13/01/2022 
n/a 
Not applicable. 
add hepatotoxicity as an important potential risk to 
the safety concerns. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/10887
Periodic Safety Update EU Single assessment - 
02/12/2021 
n/a 
PRAC Recommendation - maintenance 
/202104 
acalabrutinib 
II/0004 
Submission of the final report of the nonclinical 
11/11/2021 
08/07/2022 
SmPC 
For more information, please refer to the Summary of 
Product Characteristics. 
Study 20266648 (5336BV) (Acalabrutinib: Neutral 
Red Uptake Phototoxicity Assay in BALB/c 3T3 Mouse 
Fibroblasts), in response to the CHMP 
recommendation to submit results from a modified 
3T3 NRU phototoxicity study with adjusted 
wavelengths. SmPC sections 4.4 and 5.3 were 
updated accordingly. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IA/0010 
A.4 - Administrative change - Change in the name 
21/10/2021 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
II/0007 
Update of section 4.5 of the SmPC following 
30/09/2021 
08/07/2022 
SmPC 
Small increases in acalabrutinib maximum concentration 
submission of the final report from ACE-HV-114, an 
open-label, fixed sequence study in healthy subjects 
to assess the pharmacokinetics of acalabrutinib and 
(Cmax) and Area Under the Curve (AUC) and decreases of 
the Cmax and AUC of its active metabolite ACP-5862 were 
obserevd when acalabrutinib was co-administed with 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
moderate CYP3A inhibitors in helathy subjects. No dose 
adjustment of acalabrutinib is required when used in 
combination with moderate CYP3A inhibitors but patients 
should be monitored closely for adverse reactions. 
its active metabolite, ACP-5862, when administered 
alone and in combination with moderate CYP3A4 
inhibitors fluconazole or isavuconazole.  
In addition, the MAH took the opportunity to bring 
the PI in line with the latest QRD template version 
10.2. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
II/0006 
C.I.13 - Other variations not specifically covered 
30/09/2021 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
II/0005 
Submission of the final report from study XS-1468 to 
24/06/2021 
08/07/2022 
SmPC 
further characterise the plasma protein binding of 
acalabrutinib and its metabolite ACP-5862 in 
different species. 
Section 5.2 of the SmPC is updated accordingly to 
reflect the new plasma protein binding data. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IAIN/0003 
C.I.11.a - Introduction of, or change(s) to, the 
18/02/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0002 
B.III.1.b.3 - Submission of a new/updated or 
07/01/2021 
n/a 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
IAIN/0001 
B.I.a.1.a - Change in the manufacturer of AS or of a 
21/12/2020 
n/a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
